SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Nuvilex, Inc. (OTCQB: NVLX) announces today that it has completed the formulation of CRS2 (Alterna™), Nuvilex’s first cancer agent. Alterna™, composed of all-natural ingredients, was originally created and its initial testing driven by Knock-Out Technologies. Initial in vitro and in vivo testing of Alterna™ has been completed; the results of these tests will be announced shortly.
